SCHEMBL2806537

SCHEMBL2806537

CNc1ncc(C(=O)N[C@@]2(C(=O)NCc3ncc(Nc4c(F)cccc4C(F)(F)F)cc3Cl)CCOC2)cn1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.34
LRRK2 Q5S007 1/20 0.33
PTGES O14684 1/20 0.32
JAK1 P23458 2/20 0.32
JAK3 P52333 2/20 0.32
JAK2 O60674 1/20 0.32
OPRL1 P41146 2/20 0.32
MAPK8 P45983 2/20 0.31
MAPK9 P45984 2/20 0.31
MAPK10 P53779 2/20 0.31
RAF1 P04049 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
CNR2 P34972 3/20 0.31
MAPK14 Q16539 2/20 0.31
PTK2 Q05397 2/20 0.31
LCK P06239 1/20 0.31
KDR P35968 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2809935 0.91 BDKRB1 (0.38) P2RX7PTGESRAF1CNR2KCNH2
SCHEMBL185684 0.91 BDKRB1 (0.35) P2RX7PTGESOPRL1MAPK8MAPK9
SCHEMBL2807071 0.91 BDKRB1 (0.35) P2RX7PTGESOPRL1MAPK8MAPK9
SCHEMBL185693 0.90 FGFR4 (0.33) P2RX7LRRK2PTGESJAK1JAK3
SCHEMBL2806938 0.88 HDAC3 (0.37) LRRK2OPRL1RAF1HDAC3HDAC1
SCHEMBL2811807 0.87 BDKRB1 (0.35) P2RX7PTGESOPRL1RAF1CNR2
SCHEMBL185531 0.87 BDKRB1 (0.35) P2RX7PTGESOPRL1RAF1CNR2
SCHEMBL2805186 0.87 CNR2 (0.37) LRRK2CNR2PTK2P2RX3CYP2C9
SCHEMBL2810139 0.86 BDKRB1 (0.36) P2RX7PTGESOPRL1MAPK8MAPK9
SCHEMBL2808286 0.86 BDKRB1 (0.36) JAK1JAK3JAK2HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
EP-2401256-B1 Compounds as bradykinin B1 antagonists BOEHRINGER INGELHEIM INT (DE) 2013-04-17 EP disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131075-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 P2RX7 30/4885LRRK2 2304/4885PTGES 2696/4885
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 P2RX7 30/4885LRRK2 2304/4885PTGES 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.